Want to join the conversation?
$JNJ said about 25% of its US orthopedic and surgery business is in multi-product line agreements. These agreements perform almost two times better than single-product contract agreements. The company stated that it sees this percentage growing to 40% in the near future, which it believes will help it accelerate its business going forward.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.